GLP-1 medications can help reduce appetite and regulate blood sugar, which may aid in weight loss during menopause
Triple Agonists (GLP-1/GIP/Glucagon) Drug-Drug Interaction Table At a glance Prototype drug / retatrutide (LY3437943) Mechanism / simultaneous GLP-1R, GIPR, and glucagon receptor agonism Phase 2 weight loss (48 wk) / 24.2% mean body weight reduction vs 2.1% placebo Primary metabolic targets / obesity, MASLD/MASH, T2D, dyslipidemia Gastric emptying effect / marked slowing, peak drug interaction risk 1 to 4 h post-dose Oral drug most affected / warfarin, oral contraceptives, levothyroxine, cyclosporine Hypoglycemia risk / low monotherapy
Exception : Saxagliptin has been associated with an increased risk of hospitalisation for heart failure (SAVOR-TIMI 53 trial), and should be avoided in patients with established HF or high HF risk
Butyrate producers, The Sentinel of Gut: their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics
Compounded semaglutide delivers the same active pharmaceutical ingredient at a fraction of the price: starting at $189 per month compared to Wegovy's typical $900+ monthly cost